PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33943052-0	2021	Single-dose amikacin plus 7 days of amoxicillin/clavulanate to treat acute cystitis caused by extended-spectrum beta-lactamase-producing Escherichia coli: A retrospective cohort study.	Amoxicillin-Potassium Clavulanate Combination	36-59	EsbL	Escherichia coli	94-126	
15815007-4	2005	The strains were screened for the production of extended-spectrum beta-lactamase (ESBL) by the double-disk synergy test using a disk of amoxicillin-clavulanic acid with disks of the extended-spectrum cephalosporins and aztreonam.	Amoxicillin-Potassium Clavulanate Combination	136-163	EsbL	Escherichia coli	48-80	
35500548-0	2022	Examining the combination of cefixime and amoxicillin/clavulanate against extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli isolates.	Amoxicillin-Potassium Clavulanate Combination	42-65	EsbL	Escherichia coli	74-106	
34795702-10	2021	Fifty-four isolates of ESBL-producing E. coli showed a high level of resistance to amoxicillin clavulanic acid (83.3%), ciprofloxacin (83.3%), and ceftazidime (79.6%).	Amoxicillin-Potassium Clavulanate Combination	83-110	EsbL	Escherichia coli	23-27	
34795702-11	2021	ESBL-positive K. pneumoniae isolates were highly resistant to ciprofloxacin (75%), and amoxicillin clavulanic acid (83.3%).	Amoxicillin-Potassium Clavulanate Combination	87-114	EsbL	Escherichia coli	0-4	
30117050-0	2018	Ceftibuten plus amoxicillin-clavulanic acid for oral treatment of urinary tract infections with ESBL producing E. coli and K. pneumoniae: a retrospective observational case-series.	Amoxicillin-Potassium Clavulanate Combination	16-43	EsbL	Escherichia coli	96-100	
35451880-0	2022	In Vitro and In Vivo Activity of Amoxicillin-Clavulanate Combined with Ceftibuten or Cefpodoxime Against Extended-Spectrum beta-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae.	Amoxicillin-Potassium Clavulanate Combination	33-56	EsbL	Escherichia coli	105-137	
30532496-12	2018	Antibiogram of these ESBL-positive isolates revealed the drugs such as colistin (100%), levofloxacin (83.33%), and imipenem (66.67%) to be highly sensitive against this pathogen but drugs such as cefotaxime (100%), ceftazidime (91.67%), amoxicillin/clavulanic acid (83.33%), tetracycline (75.00%), and gentamicin (58.33%) to be very much resistant.	Amoxicillin-Potassium Clavulanate Combination	237-264	EsbL	Escherichia coli	21-25	
30117050-1	2018	This study aimed to evaluate the clinical and bacteriological effect of oral treatment with ceftibuten plus amoxicillin-clavulanic acid in patients with a urinary tract infection (UTI) caused by an extended-spectrum beta-lactamase (ESBL)-producing micro-organism.	Amoxicillin-Potassium Clavulanate Combination	108-135	EsbL	Escherichia coli	232-236	
30117050-13	2018	This case-series shows that the synergistic combination of ceftibuten plus amoxicillin-clavulanic acid may be an option for oral treatment of UTIs caused by ESBL producing E. coli or K. pneumoniae.	Amoxicillin-Potassium Clavulanate Combination	75-102	EsbL	Escherichia coli	157-161	
25716293-3	2015	ESBL producers might be susceptible to beta-lactam-beta-lactamase inhibitor (BLBLI) combination antibiotics such piperacillin-tazobactam or amoxicillin-clavulanate.	Amoxicillin-Potassium Clavulanate Combination	140-163	EsbL	Escherichia coli	0-4	
30123199-6	2018	All ESBL producers exhibited multidrug resistance (MDR) phenotype, and more than 90% of the ESBL producers were resistant to amoxicillin, amoxicillin-clavulanic acid, oxytetracycline, enrofloxacin and sulfamethoxazole/trimethoprim.	Amoxicillin-Potassium Clavulanate Combination	138-165	EsbL	Escherichia coli	92-96	
27973988-18	2017	Therefore routine secondary testing for ESBL and AmpC production by Enterobacteriaceae that are resistant to amoxicillin-clavulanic acid in primary testing could improve the accuracy of definitive antimicrobial therapy in companion animals in New Zealand.	Amoxicillin-Potassium Clavulanate Combination	109-136	EsbL	Escherichia coli	40-44	
25100821-9	2014	Reporting errors for amoxicillin-clavulanic acid and piperacillin-tazobactam in Escherichia coli infection cases were almost exclusively due to the presence of broad-spectrum- and extended-spectrum-beta-lactamase (ESBL)-producing microorganisms (79% and 20% of all errors, respectively).	Amoxicillin-Potassium Clavulanate Combination	21-48	EsbL	Escherichia coli	180-212	
19614715-7	2010	However, amoxycillin MICs were not affected by a high inoculum with non-ESBL-producing strains, whereas the MICs of amoxycillin-clavulanate (2:1 and 4:1) increased <or=four-fold for ESBL producers, using the broth and agar dilution methods.	Amoxicillin-Potassium Clavulanate Combination	116-139	EsbL	Escherichia coli	185-189	
19614715-9	2010	Similarly, at a high inoculum, only amoxycillin-clavulanate was able to maintain bactericidal rates of killing over 24 h against the ESBL-positive E. coli isolates.	Amoxicillin-Potassium Clavulanate Combination	36-59	EsbL	Escherichia coli	133-137